Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

Journal of Experimental Medicine

Volumn 208, Issue 9, 2011, Pages 1799-1807

  Schatz, Jonathan H ^a   Oricchio, Elisa ^a   Wolfe, Andrew L ^a,b   Jiang, Man ^a   Linkov, Irina ^a   Maragulia, Jocelyn ^a   Shi, Weiji ^a   Zhang, Zhigang ^a   Rajasekhar, Vinagolu K ^a   Pagano, Nen C ^a   Porco, John A ^c   Teruya Feldstein, Julie ^a   Rosen, Neal ^a   Zelenetz, Andrew D ^a   Pelletier, Jerry ^d,e   Wendel, Hans Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c Boston University   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; DOXORUBICIN; INITIATION FACTOR 4A; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; ONCOPROTEIN; PIM KINASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RAPAMYCIN; SGI 1776; SILVESTROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CAPPED RNA; MTORC1 COMPLEX, HUMAN; PIM1 PROTEIN, HUMAN; PIM1 PROTEIN, MOUSE; PIM2 PROTEIN, HUMAN; PIM2 PROTEIN, MOUSE; PROTEIN; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE; TORC1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MICE; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-PIM-1; RNA CAPS; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 80054845323     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20110846     Document Type: Article

References (36)

1. Adams, J.M., A.W. Harris, C.A. Pinkert, L.M. Corcoran, W.S. Alexander, S. Cory, R.D. Palmiter, and R.L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 318:533-538.
2. Alizadeh, A.A., M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503-511.
3. Basso, K., A.A. Margolin, G. Stolovitzky, U. Klein, R. Dalla-Favera, and A. Califano. 2005. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37:382-390.
4. Bordeleau, M.E., F. Robert, B. Gerard, L. Lindqvist, S.M. Chen, H.G. Wendel, B. Brem, H. Greger, S.W. Lowe, J.A. Porco Jr., and J. Pelletier. 2008. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118:2651-2660.
5. Cencic, R., M. Carrier, G. Galicia-Vázquez, M.E. Bordeleau, R. Sukarieh, A. Bourdeau, B. Brem, J.G. Teodoro, H. Greger, M.L. Tremblay, et al. 2009. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE. 4:e5223.
6. Chen, L.S., S. Redkar, D. Bearss, W.G. Wierda, and V. Gandhi. 2009. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 114:4150-4157.
7. Dancey, J. 2010. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 7:209-219.
8. Dancey, J.E., R. Curiel, and J. Purvis. 2009. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin. Oncol. 36(Suppl 3): S46-S58.
9. Egle, A., A.W. Harris, M.L. Bath, L. O'Reilly, and S. Cory. 2004. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood. 103:2276-2283.
10. Feldman, M.E., B. Apsel, A. Uotila, R. Loewith, Z.A. Knight, D. Ruggero, and K.M. Shokat. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7:e38
11. Fox, C.J., P.S. Hammerman, R.M. Cinalli, S.R. Master, L.A. Chodosh, and C.B. Thompson. 2003. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17:1841-1854.
12. Gómez-Abad, C., H. Pisonero, C. Blanco-Aparicio, G. Roncador, J. Bischoff, and M. Piris. 2011. PIM inhibition as a rational therapeutic approach in diffuse large B-cell lymphoma. Ann. Oncol. 22:iv136-iv137.
13. Hammerman, P.S., C.J. Fox, M.J. Birnbaum, and C.B. Thompson. 2005. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood. 105:4477-4483.
14. Hedvat, C.V., A. Hegde, R.S. Chaganti, B. Chen, J. Qin, D.A. Filippa, S.D. Nimer, and J. Teruya-Feldstein. 2002. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum. Pathol. 33:968-974.
15. Hess, G., R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, C. Gisselbrecht, A. Laurell, F. Offner, A. Strahs, A. Berkenblit, et al. 2009. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27:3822-3829.
16. Hoover, D.S., D.G. Wingett, J. Zhang, R. Reeves, and N.S. Magnuson. 1997. Pim-1 protein expression is regulated by its 5′-untranslated region and translation initiation factor elF-4E. Cell Growth Differ. 8:1371-1380.
17. Hsi, E.D., S.H. Jung, R. Lai, J.L. Johnson, J.R. Cook, D. Jones, S. Devos, B.D. Cheson, L.E. Damon, and J. Said. 2008. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk. Lymphoma. 49:2081-2090.
18. Lenz, G., G. Wright, S.S. Dave, W. Xiao, J. Powell, H. Zhao, W. Xu, B. Tan, N. Goldschmidt, J. Iqbal, et al; Lymphoma/Leukemia Molecular Profiling Project. 2008. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359:2313-2323.
19. Mavrakis, K.J., H. Zhu, R.L. Silva, J.R. Mills, J. Teruya-Feldstein, S.W. Lowe, W. Tam, J. Pelletier, and H.G. Wendel. 2008. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22:2178-2188
20. Mavrakis, K.J., A.L. Wolfe, E. Oricchio, T. Palomero, K. de Keersmaecker, K. McJunkin, J. Zuber, T. James, A.A. Khan, C.S. Leslie, et al. 2010. Genomewide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 12:372-379.
21. Mills, J.R., Y. Hippo, F. Robert, S.M. Chen, A. Malina, C.J. Lin, U. Trojahn, H.G. Wendel, A. Charest, R.T. Bronson, et al. 2008. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. USA. 105:10853-10858.
22. Morwick, T. 2010. Pim kinase inhibitors: a survey of the patent literature. Expert Opin Ther Pat. 20:193-212.
23. Nawijn, M.C., A. Alendar, and A. Berns. 2011. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer. 11:23-34.
24. O'Reilly, K.E., F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
25. Poulsen, C.B., R. Borup, F.C. Nielsen, N. Borregaard, M. Hansen, K. Grønbaek, M.B. Møller, and E. Ralfkiaer. 2005. Microarray-based classification of diffuse large B-cell lymphoma. Eur. J. Haematol. 74:453-465.
26. Rong, L., M. Livingstone, R. Sukarieh, E. Petroulakis, A.C. Gingras, K. Crosby, B. Smith, R.D. Polakiewicz, J. Pelletier, M.A. Ferraiuolo, and N. Sonenberg. 2008. Control of eIF4E cellular localization by eIF4Ebinding proteins, 4E-BPs. RNA. 14:1318-1327.
27. Rosenwald, A., G. Wright, K. Leroy, X. Yu, P. Gaulard, R.D. Gascoyne, W.C. Chan, T. Zhao, C. Haioun, T.C. Greiner, et al. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198:851-862.
28. Sawyers, C.L. 2007. Cancer: mixing cocktails. Nature. 449:993-996.
29. Smith, S.M., K. van Besien, T. Karrison, J. Dancey, P. McLaughlin, A. Younes, S. Smith, P. Stiff, E. Lester, S. Modi, et al. 2010. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J. Clin. Oncol. 28:4740-4746.
30. Sonenberg, N., and A.G. Hinnebusch. 2009. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 136:731-745.
31. Tee, A.R., B.D. Manning, P.P. Roux, L.C. Cantley, and J. Blenis. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:1259-1268.
32. Thoreen, C.C., S.A. Kang, J.W. Chang, Q. Liu, J. Zhang, Y. Gao, L.J. Reichling, T. Sim, D.M. Sabatini, and N.S. Gray. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284:8023-8032.
33. Verbeek, S., M. van Lohuizen, M. van der Valk, J. Domen, G. Kraal, and A. Berns. 1991. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell. Biol. 11:1176-1179.
34. Wendel, H.G., E. De Stanchina, J.S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, and S.W. Lowe. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332-337.
35. Wendel, H.G., R.L. Silva, A. Malina, J.R. Mills, H. Zhu, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, J. Teruya-Feldstein, J. Pelletier, and S.W. Lowe. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21:3232-3237.
36. Wright, G., B. Tan, A. Rosenwald, E.H. Hurt, A. Wiestner, and L.M. Staudt. 2003. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA. 100:9991-9996.